Log in

NASDAQ:IONSIonis Pharmaceuticals Stock Price, Forecast & News

$57.56
-1.46 (-2.47 %)
(As of 07/31/2020 04:00 PM ET)
Add
Compare
Today's Range
$57.26
Now: $57.56
$59.46
50-Day Range
$56.51
MA: $59.93
$62.95
52-Week Range
$39.32
Now: $57.56
$73.09
Volume1.05 million shs
Average Volume624,966 shs
Market Capitalization$8.02 billion
P/E Ratio52.33
Dividend YieldN/A
Beta1.61
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Read More
Ionis Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.2Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 billion
Cash Flow$2.43 per share
Book Value$11.98 per share

Profitability

Net Income$303.26 million

Miscellaneous

Employees737
Market Cap$8.02 billion
Next Earnings Date8/5/2020 (Confirmed)
OptionableOptionable
$57.56
-1.46 (-2.47 %)
(As of 07/31/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

How has Ionis Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Ionis Pharmaceuticals' stock was trading at $49.14 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IONS stock has increased by 17.1% and is now trading at $57.56.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Ionis Pharmaceuticals?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Ionis Pharmaceuticals
.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020.
View our earnings forecast for Ionis Pharmaceuticals
.

How can I listen to Ionis Pharmaceuticals' earnings call?

Ionis Pharmaceuticals will be holding an earnings conference call on Wednesday, August 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released its quarterly earnings data on Wednesday, May, 6th. The company reported ($0.35) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.12) by $0.23. The business had revenue of $133 million for the quarter, compared to analysts' expectations of $161.59 million. Ionis Pharmaceuticals had a return on equity of 12.50% and a net margin of 16.79%. Ionis Pharmaceuticals's revenue was down 55.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.62 earnings per share.
View Ionis Pharmaceuticals' earnings history
.

What price target have analysts set for IONS?

16 analysts have issued 1 year target prices for Ionis Pharmaceuticals' shares. Their forecasts range from $56.00 to $120.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $75.21 in the next year. This suggests a possible upside of 30.7% from the stock's current price.
View analysts' price targets for Ionis Pharmaceuticals
.

Has Ionis Pharmaceuticals been receiving favorable news coverage?

Press coverage about IONS stock has trended negative on Monday, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of -2.2 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Ionis Pharmaceuticals
.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), Alibaba Group (BABA), BlackRock (BLK), Gilead Sciences (GILD), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), NVIDIA (NVDA), Intercept Pharmaceuticals (ICPT) and Skyworks Solutions (SWKS).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the following people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.94%), Sumitomo Mitsui Trust Holdings Inc. (0.56%), Sicart Associates LLC (0.30%), Raymond James & Associates (0.25%), Candriam Luxembourg S.C.A. (0.18%) and Peregrine Capital Management LLC (0.14%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends for Ionis Pharmaceuticals
.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., UBS Group AG, Gateway Investment Advisers LLC, Peregrine Capital Management LLC, International Biotechnology Trust PLC, Sicart Associates LLC, DAVENPORT & Co LLC, and Candriam Luxembourg S.C.A.. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen, and Stanley T Crooke.
View insider buying and selling activity for Ionis Pharmaceuticals
.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was bought by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Nisa Investment Advisors LLC, NN Investment Partners Holdings N.V., First Quadrant L P CA, Vident Investment Advisory LLC, Vident Investment Advisory LLC, XTX Markets LLC, and Assenagon Asset Management S.A..
View insider buying and selling activity for Ionis Pharmaceuticals
.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $57.56.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $8.02 billion and generates $1.12 billion in revenue each year. The company earns $303.26 million in net income (profit) each year or $2.08 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is www.ionispharma.com.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.